Personalized cancer vaccines are getting closer to market. Merck and Moderna just showed successful manufacturing in a large ...

DME, a Phase 2 trial of BGE-102, a potential best-in-class oral NLRP3 inhibitor, in diabetic macular edema; topline results ...

Sarepta Therapeutics’ newly minted CEO Michael Severino laid out his path to returning the muscular dystrophy therapy maker ...

Profound expects full-year 2026 revenue to be at least $25.0 million; minimum gross margin projection for the year remains at ...

(NASDAQ: BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary ...

ADELAIDE, Australia, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Avance Clinical, a full-service biotech-focused global contract ...

Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on ...

Poster presentation will highlight the preclinical profile of ECC1542 and its potential for treating obesity and associated ...

CAMBRIDGE, MA / ACCESS Newswire / November 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and ...